Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology

Domenico Motola, Alberto Vaccheri, Andrea Roncadori, Monia Donati, Giulia Bonaldo, Anna Covezzoli, Piera Polidori, Stefano Bianchi

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of this multicenter prospective study was to evaluate efficacy and safety of biosimilar erythropoiesis-stimulating agents (ESAs) vs originator, based on data from clinical practice in patients with chronic kidney disease (CKD). Methods: We collected data of the patients with diagnosis of CKD on conservative treatment from nine Italian structures. Patients were enrolled applying different exclusion criteria, and various individual parameters were registered at the beginning for descriptive analysis. Patients were treated with epoetin alfa, beta, and darbepoetin as originator and epoetin zeta as biosimilar. Hemoglobin levels have been analyzed at baseline and after 3, 6, and 12 months. Descriptive statistics were used to analyze the results. Results: At baseline, 47 patients were in the biosimilar group and 57 in the originator; the basal level of hemoglobin was similar between the groups (mean Hb 9.4 and 9.3 g/dL, respectively). Median age, weight, and comorbidities were almost comparable. After 3 months, 44 patients remained in the biosimilar group and 48 in the originator; hemoglobin increase was significantly greater in patients treated with biosimilar [absolute increase 1.6 vs 1.0 g/dL, p < 0.001]. After 6 and 12 months, number of patients fall furthermore. Hemoglobin levels increased more in the biosimilar group after 6 months (2.1 vs 1.1 g/dL, p < 0.001) and 12 months (2.0 vs 1.0 g/dL, p < 0.001). Conclusions: Biosimilar ESAs have similar risk/benefit profile compared to originators. Our data are in agreement with relevant scientific literature and, on the other hand, they are in contrast with common thought that considers biosimilar less efficacious and less safe than originators.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
DOIs
Publication statusAccepted/In press - Feb 10 2018

Fingerprint

Biosimilar Pharmaceuticals
Hematinics
Nephrology
Observational Studies
Hemoglobins
Epoetin Alfa
Chronic Renal Insufficiency
Literature
Multicenter Studies
Comorbidity

Keywords

  • Biosimilar
  • Erythropoiesis-stimulating agents
  • Observational study
  • Risk/benefit profile

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs) : data from an Italian observational study in nephrology. / Motola, Domenico; Vaccheri, Alberto; Roncadori, Andrea; Donati, Monia; Bonaldo, Giulia; Covezzoli, Anna; Polidori, Piera; Bianchi, Stefano.

In: European Journal of Clinical Pharmacology, 10.02.2018, p. 1-6.

Research output: Contribution to journalArticle

Motola, Domenico ; Vaccheri, Alberto ; Roncadori, Andrea ; Donati, Monia ; Bonaldo, Giulia ; Covezzoli, Anna ; Polidori, Piera ; Bianchi, Stefano. / Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs) : data from an Italian observational study in nephrology. In: European Journal of Clinical Pharmacology. 2018 ; pp. 1-6.
@article{3e6ea68be8ea4c2cac3b2818c0260254,
title = "Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology",
abstract = "Purpose: The aim of this multicenter prospective study was to evaluate efficacy and safety of biosimilar erythropoiesis-stimulating agents (ESAs) vs originator, based on data from clinical practice in patients with chronic kidney disease (CKD). Methods: We collected data of the patients with diagnosis of CKD on conservative treatment from nine Italian structures. Patients were enrolled applying different exclusion criteria, and various individual parameters were registered at the beginning for descriptive analysis. Patients were treated with epoetin alfa, beta, and darbepoetin as originator and epoetin zeta as biosimilar. Hemoglobin levels have been analyzed at baseline and after 3, 6, and 12 months. Descriptive statistics were used to analyze the results. Results: At baseline, 47 patients were in the biosimilar group and 57 in the originator; the basal level of hemoglobin was similar between the groups (mean Hb 9.4 and 9.3 g/dL, respectively). Median age, weight, and comorbidities were almost comparable. After 3 months, 44 patients remained in the biosimilar group and 48 in the originator; hemoglobin increase was significantly greater in patients treated with biosimilar [absolute increase 1.6 vs 1.0 g/dL, p < 0.001]. After 6 and 12 months, number of patients fall furthermore. Hemoglobin levels increased more in the biosimilar group after 6 months (2.1 vs 1.1 g/dL, p < 0.001) and 12 months (2.0 vs 1.0 g/dL, p < 0.001). Conclusions: Biosimilar ESAs have similar risk/benefit profile compared to originators. Our data are in agreement with relevant scientific literature and, on the other hand, they are in contrast with common thought that considers biosimilar less efficacious and less safe than originators.",
keywords = "Biosimilar, Erythropoiesis-stimulating agents, Observational study, Risk/benefit profile",
author = "Domenico Motola and Alberto Vaccheri and Andrea Roncadori and Monia Donati and Giulia Bonaldo and Anna Covezzoli and Piera Polidori and Stefano Bianchi",
year = "2018",
month = "2",
day = "10",
doi = "10.1007/s00228-018-2428-2",
language = "English",
pages = "1--6",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs)

T2 - data from an Italian observational study in nephrology

AU - Motola, Domenico

AU - Vaccheri, Alberto

AU - Roncadori, Andrea

AU - Donati, Monia

AU - Bonaldo, Giulia

AU - Covezzoli, Anna

AU - Polidori, Piera

AU - Bianchi, Stefano

PY - 2018/2/10

Y1 - 2018/2/10

N2 - Purpose: The aim of this multicenter prospective study was to evaluate efficacy and safety of biosimilar erythropoiesis-stimulating agents (ESAs) vs originator, based on data from clinical practice in patients with chronic kidney disease (CKD). Methods: We collected data of the patients with diagnosis of CKD on conservative treatment from nine Italian structures. Patients were enrolled applying different exclusion criteria, and various individual parameters were registered at the beginning for descriptive analysis. Patients were treated with epoetin alfa, beta, and darbepoetin as originator and epoetin zeta as biosimilar. Hemoglobin levels have been analyzed at baseline and after 3, 6, and 12 months. Descriptive statistics were used to analyze the results. Results: At baseline, 47 patients were in the biosimilar group and 57 in the originator; the basal level of hemoglobin was similar between the groups (mean Hb 9.4 and 9.3 g/dL, respectively). Median age, weight, and comorbidities were almost comparable. After 3 months, 44 patients remained in the biosimilar group and 48 in the originator; hemoglobin increase was significantly greater in patients treated with biosimilar [absolute increase 1.6 vs 1.0 g/dL, p < 0.001]. After 6 and 12 months, number of patients fall furthermore. Hemoglobin levels increased more in the biosimilar group after 6 months (2.1 vs 1.1 g/dL, p < 0.001) and 12 months (2.0 vs 1.0 g/dL, p < 0.001). Conclusions: Biosimilar ESAs have similar risk/benefit profile compared to originators. Our data are in agreement with relevant scientific literature and, on the other hand, they are in contrast with common thought that considers biosimilar less efficacious and less safe than originators.

AB - Purpose: The aim of this multicenter prospective study was to evaluate efficacy and safety of biosimilar erythropoiesis-stimulating agents (ESAs) vs originator, based on data from clinical practice in patients with chronic kidney disease (CKD). Methods: We collected data of the patients with diagnosis of CKD on conservative treatment from nine Italian structures. Patients were enrolled applying different exclusion criteria, and various individual parameters were registered at the beginning for descriptive analysis. Patients were treated with epoetin alfa, beta, and darbepoetin as originator and epoetin zeta as biosimilar. Hemoglobin levels have been analyzed at baseline and after 3, 6, and 12 months. Descriptive statistics were used to analyze the results. Results: At baseline, 47 patients were in the biosimilar group and 57 in the originator; the basal level of hemoglobin was similar between the groups (mean Hb 9.4 and 9.3 g/dL, respectively). Median age, weight, and comorbidities were almost comparable. After 3 months, 44 patients remained in the biosimilar group and 48 in the originator; hemoglobin increase was significantly greater in patients treated with biosimilar [absolute increase 1.6 vs 1.0 g/dL, p < 0.001]. After 6 and 12 months, number of patients fall furthermore. Hemoglobin levels increased more in the biosimilar group after 6 months (2.1 vs 1.1 g/dL, p < 0.001) and 12 months (2.0 vs 1.0 g/dL, p < 0.001). Conclusions: Biosimilar ESAs have similar risk/benefit profile compared to originators. Our data are in agreement with relevant scientific literature and, on the other hand, they are in contrast with common thought that considers biosimilar less efficacious and less safe than originators.

KW - Biosimilar

KW - Erythropoiesis-stimulating agents

KW - Observational study

KW - Risk/benefit profile

UR - http://www.scopus.com/inward/record.url?scp=85041899397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041899397&partnerID=8YFLogxK

U2 - 10.1007/s00228-018-2428-2

DO - 10.1007/s00228-018-2428-2

M3 - Article

AN - SCOPUS:85041899397

SP - 1

EP - 6

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

ER -